Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jean-Christophe Charpentier"'
Autor:
Tatiana Balima-Koussoube, Eric Pussard, Hubert Barennes, Jean-Christophe Charpentier, Nicolas Nagot
Publikováno v:
BMJ. 332:1055-1059
Objective To compare the safety and efficacy of quinine given by the rectal route with quinine given by the intramuscular route in children with moderately severe Plasmodium falciparum malaria. Design Randomised, open, clinical trial. Setting Health
Autor:
V. Fichet, H. Auvray, Bruno Cutuli, Jean-Christophe Charpentier, C. Charra-Brunaud, Hervé Mignotte, Sylvia Giard, R. Fay, Christine Cohen-Solal-le Nir, Véronique Servent, Stephane Jacquot, Brigitte de Lafontan, Claire Lemanski
Publikováno v:
International journal of radiation oncology, biology, physics. 53(4)
To assess the long-term outcome for women with ductal carcinoma in situ of the breast treated in current clinical practice by conservative surgery with or without definitive breast irradiation.We analyzed 705 cases of ductal carcinoma in situ treated
Autor:
Pierre Fournerie, Christophe Riocreux, Patrick Rene-Corail, Jean-Luc Fanon, Didier Smadja, Florence May, Jean-Christophe Charpentier, Martine Saint-Vil, Jeannine Ketterlé, Philippe Cabre
Publikováno v:
Stroke. 32(12)
Background and Purpose — The ERMANCIA (Etude Réalisée en Martinique et Centrée sur l’Incidence de Accidents vasculaires cérébraux) study was designed to provide the first comparable epidemiological data on stroke in a black Caribbean po
Publikováno v:
Annals of allergy, asthmaimmunology : official publication of the American College of Allergy, Asthma,Immunology. 80(5)
Background Cetirizine and ebastine are two second-generation histamine H 1 antagonists undergoing evaluation for treatment of perennial rhinitis. Objective The clinical efficacy and safety of once daily cetirizine 10 mg were compared with ebastine 10
Autor:
Corine Bernaud, Jean-Michel Hotton, Claire Mounier-Vehier, Bruno Lequeuche, Carré A, Jean-Christophe Charpentier
Publikováno v:
American journal of hypertension. 11(4 Pt 1)
Poor compliance is a principal cause of treatment failure in hypertensive patients. Once-daily dosing improves compliance, but 24-h antihypertensive activity should be provided. The compliance, efficacy, and safety of amlodipine and nifedipine slow-r